SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday

SELLAS Life Sciences Group (NASDAQ:SLS) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect SELLAS Life Sciences Group to announce earnings of ($0.0450) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ:SLS opened at $11.81 on Wednesday. The stock’s 50-day moving average is $10.75 and its 200-day moving average is $6.98. SELLAS Life Sciences Group has a 52-week low of $1.39 and a 52-week high of $15.88. The company has a market cap of $2.32 billion, a P/E ratio of -51.35 and a beta of 2.48.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SLS. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of SELLAS Life Sciences Group by 38.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 408,401 shares of the company’s stock valued at $1,540,000 after purchasing an additional 114,295 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of SELLAS Life Sciences Group by 294.5% during the fourth quarter. Wells Fargo & Company MN now owns 299,305 shares of the company’s stock worth $1,128,000 after buying an additional 223,438 shares in the last quarter. Mariner LLC boosted its holdings in shares of SELLAS Life Sciences Group by 46.3% in the 4th quarter. Mariner LLC now owns 159,150 shares of the company’s stock worth $600,000 after acquiring an additional 50,344 shares in the last quarter. XTX Topco Ltd bought a new position in SELLAS Life Sciences Group in the 4th quarter valued at $447,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of SELLAS Life Sciences Group by 13.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock worth $143,000 after purchasing an additional 4,564 shares during the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.